1-Buy ZYME @ $33.
THIS HIT $37 TODAY -!!! WHERE IS THE LOVE????
Zymeworks data continue to outperform Herceptin, says Raymond James 08:02 ZYME Raymond James analyst David Novak says ESMO abstracts last night provided a preliminary look at the data Zymeworks will be disclosing on September 16 around its Phase 2 study evaluating Zanidatamab plus chemo in first-line HER2+ metastatic gastroesophageal adenocarcinomas. The company has disclosed an overall response rate of 68.2%, "significantly outperforming" the current standard of care of Herceptin plus chemo, Novak tells investors in a research note. The analyst believes efficacy data continue to support Zanidatamab as superior to Herceptin. He keeps a Strong Buy rating on Zymeworks with a $74 price target.
[/QUOTE]